405024AD2

• On August 14, 2026, Haemonetics entered into a non-exclusive supply agreement with CSL Plasma Inc. for NexSys PCS devices with Persona PLUS technology and related disposables in the U.S.
• Haemonetics is not updating its fiscal 2027 guidance and expects to discuss the agreement's impact on its November 2026 second fiscal quarter earnings call.
• The disclosure was made under Item 7.01 Regulation FD and is not deemed filed for SEC liability purposes.

7.01 Regulation FD Disclosure

• GAAP earnings per diluted share were $0.72, while adjusted earnings per diluted share were $1.14.
• Gross margin was 59.8%, flat year-over-year; operating margin was 16.9%, up slightly from 16.8%.
• Cash flow from operating activities was $52.3 million, and free cash flow was $39.1 million.
• The company raised its fiscal 2027 guidance: reported revenue growth now 5-8% (from 4-7%) and organic revenue growth now 4-7% (from 3-6%).

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Martin Madaus was elected as a director of Haemonetics Corporation on July 24, 2026, effective immediately.
• He will stand for election at the 2027 annual meeting and is expected to join the Audit and Governance and Compliance Committees.
• As a non-employee director, Madaus will receive compensation per the 2026 proxy statement, including an annual equity award of approximately $200,000.
• Shareholders at the July 24, 2026 annual meeting approved amendments to the 2019 Long-Term Incentive Plan and the 2007 Employee Stock Purchase Plan.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• The Plasma and Blood Center segments will be combined into a single Apheresis segment, and the Hospital segment will be renamed MedSurg.
• The new structure takes effect in the first quarter of fiscal year 2027, which began on March 29, 2026.
• The company posted a supplemental presentation with recast historical revenue for fiscal years 2024-2026 and recast FY2027 guidance, but did not reaffirm or update its prior guidance.
• The change was disclosed under Item 7.01 Regulation FD and Item 9.01, with the press release attached as Exhibit 99.1.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Q4 GAAP loss per diluted share was $(0.44); adjusted EPS was $1.29. Full-year GAAP EPS was $2.05; adjusted EPS was $4.96.
• Q4 organic revenue grew 4.5%; organic ex-CSL grew 8.6%. Full-year organic growth was 1.1%; organic ex-CSL growth was 9.5%.
• Fiscal 2027 guidance: reported revenue growth 4-7%, organic revenue growth 3-6%, adjusted operating margin expansion of 50-100 bps, adjusted EPS growth comparable to revenue growth, and free cash flow conversion of ~80%.
• During Q4, the company repurchased 1,579,255 shares for $100.0 million under its $500.0 million repurchase program, leaving $325.0 million remaining.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Charles J. Dockendorff informed Haemonetics on April 27, 2026, that he will not stand for re-election at the 2026 Annual Meeting of Shareholders.
• He will continue as a director and in his committee roles until the 2026 Annual Meeting.
• His decision is not the result of any disagreement with the Company.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• On March 2, 2026, Haemonetics Corporation repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026.
• The repayment was funded with cash on hand and borrowings under the company's revolving credit facility.
• No holders exercised conversion rights prior to the close of business on the second scheduled trading day before the maturity date.
• The capped call transactions related to the Notes expired upon maturity in accordance with their terms.

7.01 Regulation FD Disclosure

• Haemonetics Corporation published its 2024-2025 Corporate Responsibility Report on February 12, 2026.
• The disclosure was made under Item 7.01 Regulation FD Disclosure.
• The information is not deemed 'filed' under Section 18 of the Exchange Act and is not incorporated by reference into any filings.
• The report was signed by President and CEO Christopher A. Simon.

7.01 Regulation FD Disclosure